New Amsterdam Sciences (NAS) is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. NAS911, the company's lead compound, is being pursued for indications including idiopathic pulmonary ?brosis, in?uenza infection, wound healing, and solid tumors. New Amsterdam Sciences is devoted to developing products for both the commercial and government markets, focusing speci?cally on mass casualty biodefense applications.
Idiopathic Pulmonary Fibrosis, Substance P. NAS911, Immunology, Neurology, Acute Radiation Sickness, Influenza infection, wound healing, solid tumors,